International Cancer Conference Journal最新文献_第2页

HER2-targeted therapy is changing. HER2靶向疗法正在发生变化。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-28 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00730-1

Noriomi Matsumura

引用次数: 0

Radiotherapy for cytokeratin-positive interstitial reticulum cell (CIRC) tumor on epicardium: a case report. 心外膜细胞角蛋白阳性间质网细胞（CIRC）肿瘤放疗1例。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-27 eCollection Date: 2025-01-01 DOI: 10.1007/s13691-024-00729-8

Masahide Anada, Haruyuki Fujita, Ryou Ishikawa, Shigeo Takahashi, Syunsuke Yoshida, Takamasa Nishide, Toshifumi Kinoshita, Norimitsu Kadowaki, Toru Shibata

{"title":"Radiotherapy for cytokeratin-positive interstitial reticulum cell (CIRC) tumor on epicardium: a case report.","authors":"Masahide Anada, Haruyuki Fujita, Ryou Ishikawa, Shigeo Takahashi, Syunsuke Yoshida, Takamasa Nishide, Toshifumi Kinoshita, Norimitsu Kadowaki, Toru Shibata","doi":"10.1007/s13691-024-00729-8","DOIUrl":"https://doi.org/10.1007/s13691-024-00729-8","url":null,"abstract":"Cytokeratin-positive interstitial reticulum cell (CIRC) tumor is an extremely rare malignant neoplasm and a subtype of fibroblastic reticular cell tumor, classified within the dendritic cell tumor group. We describe a case of an epicardial CIRC tumor that was resected and subsequently recurred in the left pulmonary hilum. This recurrence was treated with immunotherapy followed by radiotherapy. A 71-year-old man with a history of colon cancer incidentally had a mass bordering the epicardium on a postoperative follow-up computed tomography scan. Pericardial tumor resection was performed due to suspected metastasis from colon cancer. Histopathologically, the patient was diagnosed as a CIRC tumor (programmed death ligand 1 expression rate > 95%). Seven months after pericardial surgery, the patient was treated with nivolumab because of local recurrence in the left pulmonary hilum, but the tumor size gradually increased. Three months after the initiation of nivolumab, the patient had a completely atelectatic left lung due to tumor invasion into the left main bronchus and was treated with external beam radiotherapy of 66 Gy in 33 fractions. One and a half months after the completion of radiotherapy, the atelectasis disappeared, and aeration was greatly improved. Three months after the completion of radiotherapy, atelectasis and pericardial effusion appeared owing to tumor regrowth, and the patient died of heart failure 2 months later. This report provides insights into the efficacy of immunotherapy and radiotherapy for CIRC tumor.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"27-34"},"PeriodicalIF":0.5,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ponatinib and prednisolone induce sustained remission in a relapsed case of mixed-phenotype acute leukemia with BCR::ABL1 fusion intolerant to dasatinib. 波纳替尼和强的松龙诱导BCR::ABL1融合对达沙替尼不耐受的混合表型急性白血病复发病例持续缓解。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-21 eCollection Date: 2025-01-01 DOI: 10.1007/s13691-024-00725-y

Hisaharu Shikata, Yuya Masuda, Kenichi Ishikawa, Masahiko Kaneko

{"title":"Ponatinib and prednisolone induce sustained remission in a relapsed case of mixed-phenotype acute leukemia with BCR::ABL1 fusion intolerant to dasatinib.","authors":"Hisaharu Shikata, Yuya Masuda, Kenichi Ishikawa, Masahiko Kaneko","doi":"10.1007/s13691-024-00725-y","DOIUrl":"https://doi.org/10.1007/s13691-024-00725-y","url":null,"abstract":"Mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion is a rare leukemia subtype exhibiting both myeloid and lymphoid traits. Standard treatment involves chemotherapy with a tyrosine kinase inhibitor (TKI). However, establishing the optimal treatment strategy for elderly patients with MPAL with BCR::ABL1 fusion is challenging due to their intolerance to intensive chemotherapy. It has not yet been determined whether therapy with a TKI and prednisolone, a combination known to be effective in elderly patients with B-lymphoblastic leukemia with BCR::ABL1 fusion is also safe and effective for MPAL with BCR::ABL1 fusion. Here we report the first example of an elderly patient with MPAL with BCR::ABL1 fusion who was treated successfully with ponatinib and prednisolone. Despite achieving complete response with dasatinib plus chemotherapy, the patient suffered a relapse during the withdrawal of dasatinib and had two episodes of gastrointestinal bleeding attributed to the dasatinib therapy, necessitating therapy discontinuation. The treatment was then switched to a regimen of ponatinib and prednisolone, and the patient achieved and maintained complete molecular remission for over seven years without any serious adverse events. This case suggests that ponatinib, with or without prednisolone, could be a potential salvage option for elderly patients with MPAL with BCR::ABL1 fusion who suffer relapse or are intolerant to dasatinib.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"7-11"},"PeriodicalIF":0.5,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of gastritis caused by immune checkpoint inhibitor treated with infliximab. 用英夫利昔单抗治疗免疫检查点抑制剂引起的胃炎病例。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-18 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00709-y

Shizu Itsukage, Noriko Kume, Aki Tajima, Takashi Okazaki, Koji Tsuta, Hideaki Tanizaki

引用次数: 0

Intraventricular ganglioneuroblastoma: an uncommon location for a rare tumour in a young adult with review of literature. 脑室内神经节神经母细胞瘤：一个罕见的位置，罕见的肿瘤在一个年轻的成年人复习文献。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-18 eCollection Date: 2025-01-01 DOI: 10.1007/s13691-024-00726-x

Tarang Patel, Garima M Anandani, Virendrakumar Meena

引用次数: 0

SMARCA4-deficient uterine tumors in young women: response to immune checkpoint inhibitors. 年轻女性SMARCA4缺陷子宫肿瘤：对免疫检查点抑制剂的反应。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-17 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00721-2

Riku Suzui, Mana Taki, Sachiko Kitamura, Masumi Sunada, Koji Yamanoi, Ryusuke Murakami, Ken Yamaguchi, Junzo Hamanishi, Sachiko Minamiguchi, Masaki Mandai

{"title":"SMARCA4-deficient uterine tumors in young women: response to immune checkpoint inhibitors.","authors":"Riku Suzui, Mana Taki, Sachiko Kitamura, Masumi Sunada, Koji Yamanoi, Ryusuke Murakami, Ken Yamaguchi, Junzo Hamanishi, Sachiko Minamiguchi, Masaki Mandai","doi":"10.1007/s13691-024-00721-2","DOIUrl":"https://doi.org/10.1007/s13691-024-00721-2","url":null,"abstract":"SMARCA4-deficient tumors have been reported in various organs and are associated with a poor prognosis. SMARCA4-deficient undifferentiated uterine sarcoma (SDUS) was first described in 2018. Conversely, loss of SMARCA4 (BRG1) expression, as observed by immunostaining, has been observed in several cases of undifferentiated endometrial carcinoma. SDUS has considerable morphologic overlap with undifferentiated endometrial carcinoma, while there are differences in their clinicopathological features. Here, we present two cases of SMARCA4-deficient uterine tumors in patients in their 20 s: SDUS (Case 1) and undifferentiated endometrial carcinoma without SMARCA4 nuclear expression (Case 2). Using comprehensive genome profiling, we found that both cases had SMARCA4 mutations, with tumor mutation burdens of 0 and 68 Muts/Mb, respectively. Case 1 had multiple lung metastases 9 months after surgery. We treated the patients with combination of an immune checkpoint inhibitor (pembrolizumab) and a multikinase inhibitor (lenvatinib), and the response to the treatment was stable. This study presents the first report on the response to immune checkpoint inhibitor and multikinase inhibitor in SDUS.Supplementary information: The online version contains supplementary material available at 10.1007/s13691-024-00721-2.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"515-519"},"PeriodicalIF":0.5,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of grade1 follicular lymphoma diagnosed by laparoscopic lymph node resection: differentiating from late lymph node recurrence of endometrial cancer. 一例通过腹腔镜淋巴结切除术确诊的一级卵泡淋巴瘤：与子宫内膜癌晚期淋巴结复发的鉴别。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-17 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00724-z

Shingo Koyama, Haruko Okamoto, Koji Yamanoi, Rin Mizuno, Masumi Sunada, Mana Taki, Ryusuke Murakami, Hiroaki Ito, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai

{"title":"A case of grade1 follicular lymphoma diagnosed by laparoscopic lymph node resection: differentiating from late lymph node recurrence of endometrial cancer.","authors":"Shingo Koyama, Haruko Okamoto, Koji Yamanoi, Rin Mizuno, Masumi Sunada, Mana Taki, Ryusuke Murakami, Hiroaki Ito, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai","doi":"10.1007/s13691-024-00724-z","DOIUrl":"https://doi.org/10.1007/s13691-024-00724-z","url":null,"abstract":"Follicular lymphoma is a common hematologic malignancy; however, it is less common among all malignant diseases and is difficult to suspect in advance due to the lack of specific clinical findings. Here, we report a case in which a late recurrence of corpus cancer was first suspected and finally diagnosed as follicular lymphoma. A 67-year-old female presented to our department with enlarged pelvic lymph nodes. She was diagnosed with breast cancer (HER2-posiotive with lymph node metastasis) and corpus cancer (endometrioid carcinoma grade 2, stage IA) 16 years prior, received definitive therapy and was followed up. A positron emission tomography scan was performed, and an accumulation of 18F-fluorodeoxyglucose (FDG) was detected in multiple lymph nodes, including the lymph nodes with no change in size or enlargement. We performed laparoscopic resection of the enlarged and FDG-accumulated lymph nodes and a pathological examination. The patient was diagnosed with follicular lymphoma (FL) grade 1 and is currently under observation at the Department of Hematology. FL can be considered when there is a discrepancy between the change in lymph node size and the degree of FDG accumulation. A pathological examination is useful for accurate diagnosis. Therefore, it is important to consider tissue collection; however, care must be taken to minimize the invasiveness of the procedure for the patient.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"525-531"},"PeriodicalIF":0.5,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case report of mucinous borderline ovarian tumor with recurrence as invasive carcinoma with high copy number alterations. 一例粘液性边界卵巢肿瘤病例报告，复发为高拷贝数改变的浸润性癌。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-17 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00722-1

Emi Wakazono, Mana Taki, Koichi Watanabe, Koji Yamanoi, Ryusuke Murakami, Nobuyuki Kakiuchi, Ken Yamaguchi, Junzo Hamanishi, Sachiko Minamiguchi, Seishi Ogawa, Masaki Mandai

{"title":"A case report of mucinous borderline ovarian tumor with recurrence as invasive carcinoma with high copy number alterations.","authors":"Emi Wakazono, Mana Taki, Koichi Watanabe, Koji Yamanoi, Ryusuke Murakami, Nobuyuki Kakiuchi, Ken Yamaguchi, Junzo Hamanishi, Sachiko Minamiguchi, Seishi Ogawa, Masaki Mandai","doi":"10.1007/s13691-024-00722-1","DOIUrl":"https://doi.org/10.1007/s13691-024-00722-1","url":null,"abstract":"Mucinous borderline ovarian tumors (MBOTs) have a very low recurrence rate and a good prognosis, especially in the early stages, but some MBOTs occasionally recur with the progression to mucinous ovarian carcinomas (MOCs). Here, we present a case of MBOT that recurred as invasive MOC within 3 years. To examine the reason for the progression from MBOT to MOC, whole-exome sequencing of our case identified identical mutations and copy number alterations in KRAS, CDKN2A, and TP53 in both the MBOT and recurrent MOC. The recurrent MOC had a greater copy number alteration burden compared to the primary MBOT. These findings suggest that MBOT may have progressed to MOC via recurrence, wherein the increased burden of copy number alterations could be its key driver. It was also suggested that TP53 mutations already present in MBOT may contribute to the increased copy number alterations leading to MOC.Supplementary information: The online version contains supplementary material available at 10.1007/s13691-024-00722-1.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"520-524"},"PeriodicalIF":0.5,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of trastuzumab deruxtecan rechallenge in a patient with HER2-positive metastatic breast cancer: a case report. HER2 阳性转移性乳腺癌患者使用曲妥珠单抗德鲁司坦再治疗的疗效：病例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-10 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00723-0

Yuko Tanaka, Naoya Ikeda, Seiji Niho, Kazuyuki Ishida

引用次数: 0

Secondary spontaneous pneumothorax during chemotherapy with bevacizumab for cervical cancer: a case report and literature review. 宫颈癌贝伐单抗化疗期间的继发性自发性气胸：病例报告和文献综述。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-05 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00696-0

Shogo Nishino, Mayu Yunokawa, Yosuke Matsuura, Atsushi Fusegi, Satoki Misaka, Yoichi Aoki, Akiko Abe, Makiko Omi, Hiroyuki Kanao

{"title":"Secondary spontaneous pneumothorax during chemotherapy with bevacizumab for cervical cancer: a case report and literature review.","authors":"Shogo Nishino, Mayu Yunokawa, Yosuke Matsuura, Atsushi Fusegi, Satoki Misaka, Yoichi Aoki, Akiko Abe, Makiko Omi, Hiroyuki Kanao","doi":"10.1007/s13691-024-00696-0","DOIUrl":"https://doi.org/10.1007/s13691-024-00696-0","url":null,"abstract":"Secondary spontaneous pneumothorax (SSP) due to bevacizumab has been reported in other malignancies but not in cervical cancer. We present the case of a 57-year-old woman with stage IIIB cervical cancer who developed SSP during bevacizumab chemotherapy. Despite complete remission with cisplatin-based chemoradiotherapy, she experienced a recurrence 9 months later. A thoracoscopic surgery was performed to remove a lung nodule and bulla. Subsequently, local cervical lesion recurrence and lung metastases were noted, and paclitaxel and carboplatin combined with bevacizumab were administered. After two cycles, a grade-1 left pneumothorax occurred, attributed to bevacizumab-induced tissue fragility. The patient improved within 7 days with conservative management. Bevacizumab was discontinued, and pneumothorax did not recur. This case highlights the rare occurrence of SSP in patients with cervical cancer treated with bevacizumab and underscores the importance of appropriate management of such patients, especially those who have undergone early thoracic surgery.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"395-400"},"PeriodicalIF":0.5,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0